Idiopathic pulmonary fibrosis: Pathogenesis and therapeutic approaches

Drugs

Volumn 64, Issue 4, 2004, Pages 405-430

  Selman, Moisés ^a   Thannickal, Victor J ^b   Pardo, Annie ^c   Zisman, David A ^d   Martinez, Fernando J ^b   Lynch III, Joseph P ^d  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN; ANTIFIBROTIC AGENT; AZATHIOPRINE; BOSENTAN; COLCHICINE; COLLAGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; GAMMA INTERFERON; IMATINIB; LU 135253; LUFIRONIL; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PIRFENIDONE; PREDNISOLONE; PREDNISONE; RECOMBINANT RELAXIN; SAFIRONIL; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ANEMIA; BLADDER DISEASE; BONE MARROW SUPPRESSION; CARCINOGENESIS; CAUSE OF DEATH; CELL DAMAGE; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DYSPNEA; EPIDEMIOLOGICAL DATA; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; GENE THERAPY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; INFECTION; INFECTION SENSITIVITY; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG ALVEOLUS EPITHELIUM; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG INJURY; LUNG TOXICITY; MUSCLE DISEASE; MYOFIBROBLAST; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATIENT; PHENOTYPE; RESPIRATORY FAILURE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STOMATITIS; SYMPTOM; SYNDROME; TARGET CELL; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; WOUND HEALING;

CLINICAL TRIALS; GENE THERAPY; HUMANS; PULMONARY FIBROSIS;

EID: 1542411333     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464040-00005     Document Type: Review

References (271)

1. Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162 (6): 2213-7
2. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164 (9): 1722-7
3. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160(3): 899-905
4. Travis WD, Matsui K, Moss J, et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24 (1): 19-33
5. Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12 (5): 1010-9
6. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 646-64
7. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157 (4 Pt 1): 1301-15
8. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2): 277-304
9. Crystal RG, Fulmer JD, Roberts WC, et al. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85 (6): 769-88
10. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298 (15): 801-9
11. Moon J, du Bois RM, Colby TV, et al. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax 1999; 54 (11): 1009-14
12. Heyneman LE, Ward S, Lynch DA, et al. Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process? AJR Am J Roentgenol 1999; 173 (6): 1617-22
13. Vourlekis JS, Brown KK, Cool CD, et al. Acute interstitial pneumonitis: case series and review of the literature. Medicine (Baltimore) 2000; 79 (6): 369-78
14. Bouros D, Nicholson AC, Polychronopoulos V, et al. Acute interstitial pneumonia. Eur Respir J 2000; 15 (2): 412-8
15. Nicholson AG, Wotherspoon AC, Diss TC, et al. Reactive pulmonary lymphoid disorders. Histopathology 1995; 26 (5): 405-12
16. Flaherty KR, Martinez FJ, Travis WD, et al. Nonspecific interstitial pneumonia (NSIP). Semin Respir Crit Care Med 2001; 22: 423-33
17. Lazor R, Vandevenne A, Pelletier A, et al. Cryptogenic organizing pneumonia: characteristics of relapses in a series of 48 patients: the Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM"O"P). Am J Respir Crit Care Med 2000; 162 (2 Pt 1): 571-7
18. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164 (2): 193-6
19. Johkoh T, Muller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999; 211 (2): 555-60
20. Swensen SJ, Aughenbaugh GL, Myers JL. Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology 1997; 205 (1): 229-34
21. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150 (4): 967-72
22. Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150 (3): 670-5
23. Hubbard R, Johnston I, Coultas DB, et al. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51 (7): 711-6
24. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996; 153 (5): 1548-52
25. Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155 (1): 242-8
26. Marshall RP, Puddicombe A, Cookson WO, et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55 (2): 143-6
27. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162 (2 Pt 1): 755-8
28. Lynch JPI, Wurfel M, Flaherty K, et al. Usual interstitial pneumonia. Semin Respir Crit Care Med 2001; 22: 357-85
29. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345 (7): 517-25
30. Wells A. Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis. Thorax 1998; 53 (12): 1080-7
31. Xaubet A, Agusti C, Luburich P, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158 (2): 431-6
32. Doherty MJ, Pearson MG, O'Grady EA, et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52 (11): 998-1002
33. Flaherty KR, Martinez FJ. The role of pulmonary function testing in pulmonary fibrosis. Curr Opin Pulm Med 2000; 6 (5): 404-10
34. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164 (1): 103-8
35. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161 (4 Pt 1): 1172-8
36. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present, and future. Chest 1996; 110 (4): 1058-67
37. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113 (2): 396-400
38. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 2001; 56 (12): 916-23
39. Lynch III JP, White E, Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001; 7 (5): 298-308
40. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134 (2): 136-51
41. Crystal RG, Bitterman PB, Mossman B, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002; 166 (2): 236-46
42. Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002; 7: 1743-61
43. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults: introduction. Thorax 1999; 54 Suppl. 1: S1-14
44. Lynch III JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155 (2): 395-420
45. Flaherty KR, Toews GB, Lynch III JP, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110(4): 278-82
46. King Jr TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164 (7): 1171-81
47. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (2): 209-14
48. Johnston ID, Gomm SA, Kalra S, et al. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom. Eur Respir J 1993; 6 (6): 891-3
49. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144 (2): 291-6
50. Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978; 65 (4): 661-72
51. Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135 (3): 696-704
52. Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135 (1): 26-34
53. Kolb M, Kirschner J, Riedel W, et al. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998; 12 (6): 1409-14
54. Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44 (4): 280-8
55. Mason RJ, Schwarz MI, Hunninghake GW, et al. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am J Respir Crit Care Med 1999; 160 (5 Pt 1): 1771-7
56. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157 (1): 199-203
57. Tukiainen P, Taskinen E, Holsti P, et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38 (5): 349-55
58. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35 (8): 593-9
59. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158 (1): 220-5
60. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124 (1): 1-8
61. Meier-Sydow J, Weiss S, Buhl R, et al. Idiopathic pulmonary fibrosis: current concepts and challenges improvement. Semin Respir Crit Care Med 1994; 15: 77-96
62. van Oortegem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7 (11): 1950-7
63. Zisman DA, Lynch III JP, Toews GB, et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117(6): 1619-26
64. O'Donnell K, Keogh B, Cantin A, et al. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1987; 136 (2): 288-92
65. Eliasson O, Cole SR, Degraff Jr AC. Adverse effects of cyclophosphamide in idiopathic pulmonary fibrosis. Conn Med 1985; 49 (5): 286-9
66. Schwartz DA, Van Fossen DS, Davis CS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149 (2 Pt 1): 444-9
67. Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993; 103 (1): 69-73
68. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102(4): 1090-4
69. Lok SS, Smith E, Doran HM, et al. Idiopathic pulmonary fibrosis and cyclosporine: a lesson from single-lung transplantation. Chest 1998; 114 (5): 1478-81
70. Fukazawa M, Kawano M, Hisano S, et al. Efficacy of cyclosporin A for idiopathic pulmonary fibrosis. Eur J Pediatr 1990; 149 (6): 441-2
71. Alton EW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83 (4): 277-9
72. Moolman JA, Bardin PG, Rossouw DJ, et al. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46 (8): 592-5
73. Venuta F, Rendina EA, Ciriaco P, et al. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation. J Heart Lung Transplant 1993; 12 (6 Pt 1): 909-14
74. Lipsky JJ. Mycophenolate mofetil. Lancet 1996; 348 (9038): 1357-9
75. Entzian P, Schlaak M, Seitzer U, et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175 (1): 41-51
76. Dubrawsky C, Dubravsky N, Withers H. The effect of colchicine on the accumulation of hydroxyproline and on lung compliance after irradiation. Radiat Res 1978; 73: 111-20
77. Rennard SI, Bitterman PB, Ozaki T, et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro: the basis of a possible therapeutic approach of the fibrotic disorders. Am Rev Respir Dis 1988; 137 (1): 181-5
78. Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72 (3): 201-9
79. Peters SG, McDougall JC, Douglas WW, et al. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103 (1): 101-4
80. Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114 (2): 507-12
81. Herbert CM, Lindberg KA, Jayson MI, et al. Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine. Lancet 1974; I (7850): 187-92
82. Uitto J, Helin P, Rasmussen O, et al. Skin collagen in patients with scleroderma: biosynthesis and maturation in vitro, and the effect of D-penicillamine. Ann Clin Res 1970; 2 (3): 228-34
83. Geismar LS, Hennessey S, Reiser KM, et al. D-penicillamine prevents collagen accumulation in lungs of rats given bleomycin. Chest 1986; 89 (3 Suppl.): 153S-4S
84. Fedullo AJ, Karlinsky JB, Snider GL, et al. Lung statics and connective tissues after penicillamine in bleomycin-treated hamsters. J Appl Physiol 1980; 49 (6): 1083-90
85. Steen VD, Medsger Jr TA, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97 (5): 652-9
86. Steen VD, Owens GR, Redmond C, et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28 (8): 882-8
87. de Clerck LS, Dequeker J, Francx L, et al. D-penicillamine therapy and interstitial lung disease in scleroderma: a long-term follow-up study. Arthritis Rheum 1987; 30 (6): 643-50
88. Jimenez S, Sigal S. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991; 18: 1496-503
89. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol 1996; 11 (2): 463-83
90. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002; 99 (9): 6292-7
91. Iyonaga K, Miyajima M, Suga M, et al. Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 1997; 182 (2): 217-24
92. Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86 (4): 1055-64
93. Kapanci Y, Desmouliere A, Pache JC, et al. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis: possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 2163-9
94. Khalil N, O'Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5 (2): 155-62
95. Nash JR, McLaughlin PJ, Butcher D, et al. Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology 1993; 22 (4): 343-7
96. Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001; 17 (6): 1220-7
97. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341 (8860): 1550-4
98. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99 (2): 111-7
99. Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156 (2 Pt 1): 631-6
100. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107 (1): 38-44
101. Legrand C, Polette M, Tournier JM, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264 (2): 326-36
102. Gandossi E, Lunven C, Berry CN. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro. Br J Pharmacol 2000; 129 (5): 1021-7
103. Nagata M, Horita S, Shu Y, et al. Phenotypic characteristics and cyclin-dependent kinase inhibitors repression in hyperplastic epithelial pathology in idiopathic focal segmental glomerulosclerosis. Lab Invest 2000; 80 (6): 869-80
104. Schwartz MM, Evans J, Bain R, et al. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 1999; 10 (9): 1900-7
105. Kinnman N, Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 2002; 7: d496-503
106. Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta (1) in cystic fibrosis liver disease. Am J Pathol 2002; 160 (5): 1705-15
107. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138 (5): 1257-65
108. Bensadoun ES, Burke AK, Hogg JC, et al. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154 (6 Pt 1): 1819-28
109. Fukuda Y, Basset F, Ferrans VJ, et al. Significance of early intra-alveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis. Hum Pathol 1995; 26 (1): 53-61
110. Paakko P, Kaarteenaho-Wiik R, Pollanen R, et al. Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia. Am J Respir Crit Care Med 2000; 161 (3 Pt 1): 967-72
111. King Jr TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164 (6): 1025-32
112. Harris J. Differentiated cells and the maintenance of tissues. In: Alberts J, Bray D, Lewis J, et al., editors. Molecular biology of the cell. New York: Garland Publishing, 2002: 1139-93
113. Desmouliere A, Redard M, Darby I, et al. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146 (1): 56-66
114. Lorena D, Uchio K, Costa AM, et al. Normal scarring: importance of myofibroblasts. Wound Repair Regen 2002; 10 (2): 86-92
115. Kuhn III C, Boldt J, King Jr TE, et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140 (6): 1693-703
116. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971; 27 (5): 549-50
117. Walker GA, Guerrero IA, Leinwand LA. Myofibroblasts: molecular crossdressers. Curr Top Dev Biol 2001; 51: 91-107
118. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol 1994; 124 (4): 401-4
119. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261 (9): 4337-45
120. Zhang K, Rekhter MD, Gordon D, et al. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis: a combined immunohistochemical and in situ hybridization study. Am J Pathol 1994; 145 (1): 114-25
121. Finlay GA, Thannickal VJ, Fanburg BL, et al. Transforming growth factor-beta 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor. J Biol Chem 2000; 275 (36): 27650-6
122. Thannickal VJ, Aldweib KD, Rajan T, et al. Upregulated expression of fibroblast growth factor (FGF) receptors by transforming growth factor-beta1 (TGF-beta1) mediates enhanced mitogenic responses to FGFs in cultured human lung fibroblasts. Biochem Biophys Res Commun 1998; 251 (2): 437-41
123. Heino J, Ignotz RA, Hemler ME, et al. Regulation of cell adhesion receptors by transforming growth factor-beta: concomitant regulation of integrins that share a common beta 1 subunit. J Biol Chem 1989; 264 (1): 380-8
124. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem 1995; 270 (51): 30334-8
125. Thannickal VJ, Larios JM, Fanburg BL. H2O2 production by myofibroblasts is dependent on Src kinase (s) and actin cytoskeletal regulation. Chest 2001; 120: 32S-3S
126. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331 (19): 1286-92
127. Raghu G, Chen YY, Rusch V, et al. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. Am Rev Respir Dis 1988; 138 (3): 703-8
128. Ramos C, Montano M, Garcia-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001; 24 (5): 591-8
129. Jordana M, Schulman J, McSharry C, et al. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 1988; 137 (3): 579-84
130. Torry DJ, Richards CD, Podor TJ, et al. Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue. J Clin Invest 1994; 93 (4): 1525-32
131. Lappi-Blanco E, Soini Y, Paakko P. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999; 177 (6): 367-76
132. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995; 147 (6): 1759-69
133. Selman M, Ruiz V, Cabrera S, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis: a prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279 (3): L562-74
134. Hayashi T, Stetler-Stevenson WG, Fleming MV, et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996; 149 (4): 1241-56
135. Fukuda Y, Ishizaki M, Kudoh S, et al. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 1998; 78 (6): 687-98
136. Fukuda Y, Mochimaru H, Terasaki Y, et al. Mechanism of structural remodeling in pulmonary fibrosis. Chest 2001; 120 (1 Suppl.): 41S-3S
137. Uhal BD, Joshi I, True AL, et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995; 269 (6 Pt 1): L819-28
138. Uhal BD, Joshi I, Hughes WF, et al. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998; 275 (6 Pt 1): L1192-9
139. Wang R, Ramos C, Joshi I, et al. Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol 1999; 277 (6 Pt 1): L1158-64
140. Suganuma H, Sato A, Tamura R, et al. Enhanced migration of fibroblasts derived from lungs with fibrotic lesions. Thorax 1995; 50 (9): 984-9
141. Miki H, Mio T, Nagai S, et al. Fibroblast contractility: usual interstitial pneumonia and nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000; 162 (6): 2259-64
142. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95 (4): 1861-8
143. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/ fibroblastic cross-talk disorder. Respir Res 2002; 3 (1): 3
144. Brouty-Boye D, Pottin-Clemenceau C, Doucet C, et al. Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 2000; 30 (3): 914-9
145. Buckley CD, Pilling D, Lord JM, et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 22 (4): 199-204
146. Kaufman J, Graf BA, Leung EC, et al. Fibroblasts as sentinel cells: role of the CDcd40-CDcd40 ligand system in fibroblast activation and lung inflammation and fibrosis. Chest 2001; 120 (1 Suppl.): 53S-5S
147. Cornelissen AM, Von den Hoff JW, Maltha JC, et al. Effects of interferons on proliferation and collagen synthesis of rat palatal wound fibroblasts. Arch Oral Biol 1999; 44 (7): 541-7
148. Narayanan AS, Whithey J, Souza A, et al. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992; 101 (5): 1326-31
149. Okada T, Sugie I, Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993; 12 (2): 87-91
150. Eickelberg O, Pansky A, Koehler E, et al. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J 2001; 15 (3): 797-806
151. Oldroyd SD, Thomas GL, Gabbiani G, et al. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 1999; 56 (6): 2116-27
152. Tamai K, Ishikawa H, Mauviel A, et al. Interferon-gamma coordinately upregulates matrix metalloprotease (MMP)-1 and MMP-3, but not tissue inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes. J Invest Dermatol 1995; 104 (3): 384-90
153. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulalion of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21 (5): 791-808
154. Nagahori T, Dohi M, Matsumoto K, et al. Interferon-gamma upregulates the c-Met/hepatocyte growth factor receptor expression in alveolar epithelial cells. Am J Respir Cell Mol Biol 1999; 21 (4): 490-7
155. Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999; 14 (2): 251-7
156. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341 (17): 1264-9
157. Brown K, Schwartz M. Future directions in the treatment of idiopathic pulmonary fibrosis. In: Lynch III JP, editor. Idiopathic pulmonary fibrosis. New York: Marcel Dekker Inc., 2004: 701-34
158. Karla S, Utz JP, Ryu JH. Interferon-gamma 1B in the treatment of advanced idiopathic pulmonary fibrosis [abstract]. Chest 2001; 120: S184
159. Raghu G, Spada C, Otaki Y, et al. Interferon gamma in the treatment of advanced idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonia (NSIP-F): prospective, preliminary clinical observations in one center [abstract]. Chest 2001; 120: S185
160. Dimadi A, Rapti A, Latsi P, et al. Preliminary results of a prospective, multicentric randomized study comparing interferon gamma-1b (INF-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis [abstract]. Eur Respir J 2003; 22 (s45): 197
161. Raghu C, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350 (2): 125-33
162. Chen ES, Greenlee BM, Wills-Karp M, et al. Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 2001; 24 (5): 545-55
163. Awad M, Pravica V, Perrey C, et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999; 60 (4): 343-6
164. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291 (1): 367-73
165. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276 (2 Pt 1): L311-8
166. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113(1): 72-6
167. Cain WC, Stuart RW, Lefkowitz DL, et al. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998; 20 (12): 685-95
168. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1061-9
169. Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41 (12): 1118-23
170. Azuma A, Tsuboi E, Abe S, et al. A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis [abstract]. Am J Respir Crit Care Med 2002; 165: A729
171. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002; 76 (3): 234-42
172. MacNee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995; 50 Suppl. 1: S53-8
173. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on
174. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156 (6): 1897-901
175. Demedts M, Behr J, Costabel U. IFIGENIA: an international study of N-acetylecysteine (NAC) in idiopathic pulmonary fibrosis: layout and characteristics of patients [abstract]. Am J Respir Crit Care Med 2001; 163: A708
176. Panos RJ, Rubin JS, Csaky KG, et al. Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest 1993; 92 (2): 969-77
177. Ulich TR, Yi ES, Longmuir K, et al. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 1994; 93 (3): 1298-306
178. Atabai K, Ishigaki M, Geiser T, et al. Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am J Physiol Lung Cell Mol Physiol 2002; 283 (1): L163-9
179. Yano T, Deterding RR, Simonet WS, et al. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol 1996; 15 (4): 433-42
180. Yi ES, Williams ST, Lee H, et al. Keratinocyte growth factor ameliorates radiation-and bleomycin-induced lung injury and mortality. Am J Pathol 1996; 149 (6): 1963-70
181. Deterding RR, Havill AM, Yano T, et al. Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. Proc Assoc Am Physicians 1997; 109 (3): 254-68
182. Mizuno S, Kurosawa T, Matsumoto K, et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998; 101 (9): 1827-34
183. Sato M, Kakubari M, Kawamura M, et al. The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide. Biochem Pharmacol 2000; 59 (6): 681-90
184. Matsuda Y, Matsumoto K, Yamada A, et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology 1997; 26 (1): 81-9
185. Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin: a morphologic study. Am J Respir Crit Care Med 1997; 156 (6): 1937-44
186. Dohi M, Hasegawa T, Yamamoto K, et al. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162 (6): 2302-7
187. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418 (6893): 41-9
188. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105 (3): 369-77
189. Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128 (24): 5181-8
190. Davies JC, Potter M, Bush A, et al. Bone marrow stem cells do not repopulate the healthy upper respiratory tract. Pediatr Pulmonol 2002; 34 (4): 251-6
191. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engrafment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100 (14): 8407-11
192. Kohyama T, Liu X, Wen FQ, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002; 26 (6): 694-701
193. Zeldin DC. The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165 (2): 146-7
194. Fine A, Poliks CF, Donahue LP, et al. The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J Biol Chem 1989; 264 (29): 16988-91
195. Kohyama T, Ertl RF, Valenti V, et al. Prostaglandin E (2) inhibits fibroblast chemotaxis. Am J Physiol Lung Cell Mol Physiol 2001; 281 (5): L1257-63
196. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341 (8851): 989-90
197. Christman JW, Christman BW, Shepherd VL, et al. Regulation of alveolar macrophage production of chemoattractants by leukotriene B4 and prostaglandin E2. Am J Respir Cell Mol Biol 1991; 5 (3): 297-304
198. Dubois CM, Bissonnette E, Rola-Pleszczynski M. Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor: autoregulatory role of leukotriene B4. Am Rev Respir Dis 1989; 139 (5): 1257-64
199. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002; 165 (2): 229-35
200. Wilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996; 97 (8): 1827-36
201. Ozaki T, Hayashi H, Tani K, et al. Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992; 145 (1): 85-91
202. Garcia JG, Griffith DE, Cohen AB, et al. Alveolar macrophages from patients with asbestos exposure release increased levels of leukotriene B4. Am Rev Respir Dis 1989; 139 (6): 1494-501
203. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340 (3): 197-206
204. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39 (9): 1496-502
205. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2): 600-7
206. Desmouliere A, Badid C, Bochaton-Piallat ML, et al. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int J Biochem Cell Biol 1997; 29 (1): 19-30
207. Tan A, Levrey H, Dahm C, et al. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999; 159 (1): 220-7
208. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83 (5): 490-500
209. Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161 (1): 17-26
210. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104 (3): 317-24
211. Oberti F, Pilette C, Rifflet H, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997; 26 (6): 1363-71
212. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133 (7): 1172-80
213. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41 (5): 343-70
214. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990; 265 (18): 10681-5
215. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98 (12): 2739-45
216. Unemori EN, Bauer EA, Amento EP. Relaxin alone and in conjunction with interferon-gamma decreases collagen synthesis by cultured human scleroderma fibroblasts. J Invest Dermatol 1992; 99 (3): 337-42
217. Williams EJ, Benyon RC, Trim N, et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001; 49 (4): 577-83
218. Unemori EN, Beck LS, Lee WP, et al. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 1993; 101 (3): 280-5
219. Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132 (11): 871-9
220. Yokozeki M, Baba Y, Shimokawa H, et al. Interferon-gamma inhibits the myofibroblastic phenotype of rat palatal fibroblasts induced by transforming growth factor-beta1 in vitro. FEBS Lett 1999; 442(1): 61-4
221. Wang YJ, Wang SS, Bickel M, et al. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol 1998; 152 (1): 279-87
222. Godichaud S, Krisa S, Couronne B, et al. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology 2000; 31 (4): 922-31
223. Yata Y, Gotwals P, Koteliansky V, et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002; 35 (5): 1022-30
224. Denis M. Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology 1994; 82 (4): 584-90
225. Wang Q, Wang Y, Hyde DM, et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 1999; 54 (9): 805-12
226. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163 (10): 5693-9
227. Rippe RA, Schrum LW, Stefanovic B, et al. NF-kappaB inhibits expression of the alpha1 (I) collagen gene. DNA Cell Biol 1999; 18 (10): 751-61
228. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J Clin Invest 1995; 96 (1): 250-9
229. Fujita M, Shannon J, Morikawa K, et al. Overexpression of TNF-alpha in the lungs protects against pulmonary fibrosis induced by bleomycin on TGF-beta [abstract]. Am J Respir Crit Care Med 2002; 165: A42
230. Piguet PF, Collart MA, Grau GE, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170 (3): 655-63
231. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7 (3): 515-8
232. Zhang Y, Lee TC, Guillemin B, et al. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993; 150 (9): 4188-96
233. Piguet PF, Ribaux C, Karpuz V, et al. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143 (3): 651-5
234. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163 (3): 1521-8
235. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313): 1187-93
236. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002; 16 (2): 111-48
237. Niden A, Koss MN, Boylen CT, et al. An open label pilot study to determine the potential efficacy of TNFR: FC (Enbrel, etanercept) in the treatment of usual interstitial pneumonitis [abstract]. Am J Respir Crit Care Med 2002; 165: A728
238. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098-104
239. Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002; 99 (1): 381-3
240. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001; 116 (3): 417-25
241. Shahar I, Fireman E, Topilsky M, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999; 21 (11): 759-75
242. Tangkijvanich P, Tam SP, Yee Jr HF. Wound-induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rho-kinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology 2001; 33 (1): 74-80
243. Hocher B, Schwarz A, Fagan KA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000; 23 (1): 19-26
244. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997; 16 (2): 187-93
245. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002; 15 (2 Pt 1): 164-9
246. Tostes RC, Touyz RM, He G, et al. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002; 39 (6): 892-900
247. Park SH, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156 (2 Pt 1): 600-8
248. Mutsaers SE, Marshall RP, Goldsack NR, et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998; 11 (2-3): 221-5
249. Nguyen QT, Colombo F, Rouleau JL, et al. LU135252, an endothelin (A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol 2000; 130 (7): 1525-30
250. Cambrey AD, Harrison NK, Dawes KE, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994; 11 (4): 439-45
251. Odoux C, Crestani B, Lebran G, et al. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med 1997; 156 (5): 1429-35
252. Nguyen L, Ward WF, Ts'ao CH, et al. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med 1994; 205 (1): 80-4
253. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000; 161 (6): 1999-2004
254. Shihab FS, Bennett WM, Tanner AM, et al. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52 (3): 660-73
255. Ward WF, Molteni A, Ts'ao CH, et al. Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1992; 22 (3): 623-5
256. Wei HS, Li DG, Lu HM, et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl (4). World J Gastroenterol 2000; 6 (4): 540-5
257. Peters H, Border WA, Noble NA. Targeting TGF-beta over-expression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54 (5): 1570-80
258. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103 (6): 789-91
259. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56 (2): 714-9
260. Carrillo G, Estrada A, Mejia M, et al. Inhaled beclomethasone and colchicine (IBC) versus inhaled beclomethasone, colchicine and captopril (IBCCAP) in patients with idiopathic pulmonary fibrosis (IPF) [abstract]. Am J Respir Crit Care Med 2000; 161: A528
261. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5 (2): 226-30
262. Yang J, Dai C, Liu Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther 2001; 8 (19): 1470-9
263. Terada Y, Hanada S, Nakao A, et al. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int Suppl 2002; 61 Suppl. 1: 94-8
264. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104 (1): 5-11
265. Liu M, Suga M, Maclean AA, et al. Soluble transforming growth factor-beta type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of Bronchiolitis obliterans. Am J Respir Crit Care Med 2002; 165 (3): 419-23
266. Sisson TH, Hattori N, Xu Y, et al. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999; 10 (14): 2315-23
267. Verrecchia F, Rossert J, Mauviel A. Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. J Invest Dermatol 2001; 116 (5): 755-63
268. Arias M, Lahme B, Van de Leur E, et al. Adenoviral delivery of an antisense RNA complementary to the 3′ coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ 2002; 13 (6): 265-73
269. Sunamoto M, Kuze K, Tsuji H, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress collagen accumulation in experimental glomerulonephritis. Lab Invest 1998; 78 (8): 967-72
270. Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 2000; 58 (5): 1885-92
271. Martens JR, Reaves PY, Lu D, et al. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci U S A 1998; 95 (5): 2664-9